Takeda to lay off 640 workers in Massachusetts as part of multiyear overhaul

Takeda’s multiyear “efficiency program” is in full swing.

The Japanese pharma is set to let go a total of 641 workers in Massachusetts: 495 in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

March 11, 2024

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit | Psychedelic Invest

–Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” – – Highlights preclinical work done to support selection

October 9, 2023

MemorialCare Deploys Abridge’s GenAI Clinical Documentation Across Enterprise

What You Should Know: – MemorialCare, a healthcare system in Southern California, announced today a partnership with Abridge, a company pioneering the use of generative

April 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.